SWOG S1605

Primary Category:

Treatment Protocols

Disease Category:

Bladder, Genitourinary

Status:

Closed

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Effective, July 5, 2019, study S1605 is permanently closed to accrual.

NCT#02844816